Memorial Sloan Kettering Cancer Center · company speakers →
Dr. Isabelle Riviere will discuss from an academia perspective the challenges faced when taking novel platforms into the clinic. Specifically, she will provide discussion regarding how they have approached investigational new drug (IND) filings with respect to products that require viral vector engineering and gene editing.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →